GenePeeks Expands Distribution to India with Exclusive Agreement with CORE Diagnostics
New Delhi October 24, 2017 – GenePeeks, Inc., a computational genomics company focused on transforming disease risk analysis, today announced an exclusive distribution agreement with CORE Diagnostics, a next-generation diagnostics provider committed to bringing best-in-class clinical technology and innovation to India.
This new distribution agreement furthers GenePeeks’ goal of expanding access to its breakthrough preconception screen and advanced analytics platform in new markets around the world. CORE will exclusively offer GenePeeks’ preconception screen in their extensive market of twenty-nine states and seven union territories across India, greatly expanding GenePeeks global footprint. Demand for preconception screening and care in India is increasing, particularly as awareness of heritable disease risk grows.
“GenePeeks is delighted to add CORE Diagnostics to our list of outstanding global partners,” said Anne Morriss, Co-founder and Chief Executive Officer of GenePeeks. “We look forward to working with the exceptional CORE team to address the European bias embedded in traditional screening and help Indian families better understand their risk of conceiving a child with a serious genetic disease.”
Zoya Brar, co-founder and managing director of CORE Diagnostics stated, “We are excited to partner with GenePeeks to expand our portfolio of innovative testing services and support the growing interest from Indian families and their healthcare providers in preconception screening. GenePeeks’ technology provides a unique opportunity to identify risk to Indian families that were often uncharacterized historically and hidden from clinical view.”